PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 14, 2018Expert Review of Cardiovascular TherapyOpen Access

Recent advances in the treatment of Brugada syndrome

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with Brugada syndrome (BrS)

Design

Review

Key result

Recent advances in Brugada syndrome therapy highlight ICD as first-line treatment, with pharmacological approaches and radiofrequency ablation serving as important adjuncts.

Authors

MAMariana ArgenzianoCACharles Antzelevitch

Discussion

Loading...

Member takes

Overview

Supports ICD-first strategy in Brugada syndrome; leaves open efficacy of novel Ito blockers pending randomized trials.

Structured PICO

P
Population
Patients with Brugada syndrome (BrS)
I
Intervention
Implantable cardioverter defibrillator (ICD), pharmacological therapy (beta-adrenergic agents, phosphodiesterase III inhibitors, Ito inhibitors), and radiofrequency ablation

This review summarizes current treatments for Brugada syndrome, emphasizing ICDs as first-line therapy and highlighting the need for novel cardio-selective Ito blockers.

Cite This Study

Argenziano et al. (2018) conducted a review in Brugada syndrome. ICD, pharmacological therapy, and radiofrequency ablation was evaluated. Recent advances in Brugada syndrome therapy highlight ICD as first-line treatment, with pharmacological approaches and radiofrequency ablation serving as important adjuncts.

synapsesocial.com/papers/6a0e59867b06478e784c2a82https://doi.org/10.1080/14779072.2018.1475230
View Full Paper
Ask AI
Bookmark
Share